Convenient administration for joint and connective tissue support, used extensively in Russian clinical practice for degenerative conditions with established safety profile
clinical
0 views
Cartalax
Cartalax (AED peptide, T-31) is a synthetic tripeptide consisting of Alanine-Glutamate-Aspartate, developed by Professor Vladimir Khavinson as part of the bioregulatory peptide family.
Overview
Cartalax (AED peptide, T-31) is a synthetic tripeptide consisting of Alanine-Glutamate-Aspartate, developed by Professor Vladimir Khavinson as part of the bioregulatory peptide family. Originally isolated from kidney tissue and found in the alpha-1 chain of type XI collagen, Cartalax has shown potential in supporting cartilage, connective tissue, and cellular regeneration through modulation of proliferation markers and apoptosis pathways.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
AED peptideT-31Ala-Glu-Asp tripeptideAlanine-Glutamate-AspartateKhavinson bioregulator peptide
Status: Research compound - Khavinson bioregulator with Russian clinical use; not FDA approved
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Cartilage and connective-tissue bioregulationShort-peptide (Khavinson) bioregulatorsCellular regeneration / aging research
Available Evidence
Animal
The AED tripeptide belongs to the Khavinson short-peptide bioregulator family; research (largely Russian-language) reports tissue-specific modulation of proliferation and apoptosis in cartilage/connective-tissue models, but independent English-language peer-reviewed validation is very limited.
In Vitro
Cell models report the AED peptide influences proliferation markers and apoptosis pathways relevant to cartilage biology; published mechanistic detail is sparse.
Uncertain
Claims of cartilage regeneration, joint repair, and anti-aging effects are largely promotional; no rigorous clinical evidence supports them.
Benefits & Effects
No side effects data available yet.
This peptide may have limited safety data.
Limitations & Open Questions
Published evidence is extremely limited: most information comes from commercial peptide vendors and Russian-language bioregulator literature. No randomized clinical trials, no pharmacokinetic data in indexed journals, and no independent replication of claimed tissue-specific effects.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
1 capsule (100mcg)
Route: Oral
Half-life: 20-40 minutes (short-acting bioregulator)
Research Protocols
Standard Protocol
- Dose
- 1 capsule (100mcg)
- Frequency
- Daily with meals
- Route
- Oral
Intensive Support
- Dose
- 2 capsules (200mcg)
- Frequency
- Daily with meals
- Route
- Oral
Maintenance
- Dose
- 1 capsule (100mcg)
- Frequency
- Every other day with food
- Route
- Oral
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is Cartalax FDA approved?
No. Cartalax (AED peptide) is not approved by any major regulatory authority and is sold only as a research compound.
Does Cartalax regenerate cartilage?
There is no clinical evidence in humans. Claims rest on limited bioregulator-peptide research, mostly from the Khavinson school, and remain unproven.
Research Citations
1
Neuronal Differentiation Study (2022)
(2022)
2
Bone Marrow Stem Cell Study (2021)
(2021)
3
Kidney Cell Culture Research (2020)
(2020)
Related Resources
Quick Facts
Mechanism
Each capsule contains 0.1mg (100mcg) of AC-4 peptide complex. Specialized formulation designed to survive digestion and provide systemic bioregulatory effects.
Safety Information
Take with meals as directed by Russian manufacturers to optimize tolerance. No reported side effects in Russian clinical use when taken properly. Well-tolerated even in elderly patients. Can be combined with conventional treatments. No drug dependence reported.
Citations
31.Neuronal Differentiation Study (2022)
(2022)
2.Bone Marrow Stem Cell Study (2021)
(2021)
3.Kidney Cell Culture Research (2020)
(2020)